Provides information about patient risk and may inform post transplant immunosuppression strategies
This enhanced risk assessment is the first test of its kind to provide information about patient risk of early acute rejection with high specificity (NPV= 96.7); based on a patient’s unique gene profile prior to transplant.1 Data from this test may help clinicians make more informed decisions about post-transplant management and better balance the risk of rejection against the adverse effects of over-immunosuppression.
Key features and benefits
- Seamless integration: Minimally invasive blood draw which may be performed concurrently with other pre-transplant labs
- Quick results: Results available in as little as 72 hours of sample receipt
- Impact on cost of care: Adverse events in the first 60 days after transplant can cost hospitals as much as $10k per episode. Tools like the Pre-Transplant Risk Assessment Assay, which enable patient risk assessment, may provide opportunities for health system savings2
- User-friendly analysis: Provides easy to interpret results (high risk vs low risk)
- Broad gene coverage: Utilizes a proprietary algorithm comprised of 29 mRNA markers to assess risk
Improving outcomes: Conversations with thought leaders in transplantation
Key discussion points include:
- Challenges with immunosuppression management
- Advantages of tools that minimize adverse effects of immunosuppression
- Limitations of traditional testing
Challenges with standardized immunosuppression protocols
Broad clinical and demographic features are a routine part of care for most Americans living with a kidney transplant. While effective in reducing overall rates of rejection, such protocols can also result in:
- Over-immunosuppression, which may lead to poor long-term outcomes3
- Patient complications such as toxicity, cancer and serious infections4
- Considerable costs to the healthcare system2
Personalized consultative service and support
- Seamless service enabling our customers to deliver more personalized, responsive care that can improve outcomes
- Support for system access, result interpretation, and administrative questions
- We provide administrative support through service implementation to help enable a successful experience
- Gallon L, Chang A, Kattan M, Donovan M. (2023, November 2). Multi-center international study to validate a pre-transplant blood-based NGS signature predicting risk of acute rejection after kidney transplant. 2023 American Society of Nephrology Meeting, Philadelphia, PA, United States. KW23_LBCTs.pdf (asn-online.org)
- Famure O, Kim ED, Au M, et al. What Are the Burden, Causes, and Costs of Early Hospital Readmissions After Kidney Transplantation?. Prog Transplant. 2021;31(2):160-167. doi:10.1177/15269248211003563.
- Wojciechowski D, Wiseman A. Long-Term Immunosuppression Management: Opportunities and Uncertainties. Clin J Am Soc Nephrol. 2021;16(8):1264-1271. doi:10.2215/CJN.15040920.
- Szumilas K, Wilk A, Wiśniewski P, et al. Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation. Int J Mol Sci. 2023;24(12):10301. Published 2023 Jun 18. doi:10.3390/ijms241210301.
The One Lambda Laboratories Pre-Transplant Risk Assessment (PTRA) assay is a test that was developed and validated by One Lambda Laboratories. This laboratory-developed test (LDT) is used for clinical purposes by the CLIA-certified laboratory performing the test. This test has not been cleared or approved by the FDA as an in vitro diagnostic test.
Testing protocols vary by transplant center and a patient’s level of risk. This presentation is offered for informational purposes only and does not reflect all available diagnostic procedures or treatments and is not meant to be a substitute for advice from a qualified healthcare professional.